These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 24014072)

  • 21. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update.
    Franchini M; Coppola A; Rocino A; Santagostino E; Tagliaferri A; Zanon E; Morfini M;
    Semin Thromb Hemost; 2013 Oct; 39(7):752-66. PubMed ID: 24022806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors in childhood hemophilia A: genetic and treatment-related risk factors for development and eradication.
    DiMichele DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S30-3. PubMed ID: 23109404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune tolerance induction in patients with hemophilia A.
    Astermark J
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acquired hemophilia in the patient suffering from rheumatoid arthritis: case report.
    Drobiecki A; Pasiarski M; Hus I; Sokołowska B; Wątek M
    Blood Coagul Fibrinolysis; 2013 Dec; 24(8):874-80. PubMed ID: 24042266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spontaneous disappearance of high titre factor VIII inhibitor 15 years after unsuccessful ITI.
    Thom K; Male C; Falger J; Pabinger I
    Hamostaseologie; 2009 May; 29(2):149-50. PubMed ID: 19404512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
    Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
    Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitors in mild/moderate haemophilia A: an update.
    Franchini M; Salvagno GL; Lippi G
    Thromb Haemost; 2006 Aug; 96(2):113-8. PubMed ID: 16894451
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.
    Pautard B; D'Oiron R; Li Thiao Te V; Lavend'homme R; Saint-Remy JM; Peerlinck K; Jacquemin M
    J Thromb Haemost; 2011 Jun; 9(6):1163-70. PubMed ID: 21645224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Requirements for immune recognition and processing of factor VIII by antigen-presenting cells.
    van Haren SD; Wroblewska A; Fischer K; Voorberg J; Herczenik E
    Blood Rev; 2012 Jan; 26(1):43-9. PubMed ID: 22036515
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How we treat a hemophilia A patient with a factor VIII inhibitor.
    Kempton CL; White GC
    Blood; 2009 Jan; 113(1):11-7. PubMed ID: 18820129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
    Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
    Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunobiology of inhibitor development in hemophilia A.
    Fijnvandraat K; Bril WS; Voorberg J
    Semin Thromb Hemost; 2003 Feb; 29(1):61-8. PubMed ID: 12640567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of antibodies to factor VIII in hemophilia A patients treated by immune tolerance therapy.
    Scandella D; Reyes H; Felch M; Sakurai Y
    Haematologica; 2000 Oct; 85(10 Suppl):86-8. PubMed ID: 11187882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory antibodies in hemophilia A.
    Pratt KP
    Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of the bleeding inhibitor patient.
    Astermark J
    Semin Thromb Hemost; 2003 Feb; 29(1):77-86. PubMed ID: 12640569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.